Caruso Giuseppe, Wagar Matthew K, Hsu Heng-Cheng, Hoegl Jorge, Rey Valzacchi Guido Martin, Fernandes Andreina, Cucinella Giuseppe, Sahin Aker Seda, Jayraj Aarthi S, Mauro Jessica, Pareja Rene, Ramirez Pedro T
Division of Gynecologic Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Int J Gynecol Cancer. 2024 Dec 2;34(12):1946-1970. doi: 10.1136/ijgc-2024-005579.
Cervical cancer is a major global health issue, ranking as the fourth most common cancer in women worldwide. Depending on stage, histology, and patient factors, the standard management of cervical cancer is a combination of treatment approaches, including (fertility- or non-fertility-sparing) surgery, radiotherapy, platinum-based chemotherapy, and novel systemic therapies such as bevacizumab, immune checkpoint inhibitors, and antibody-drug conjugates. While ambitious global initiatives seek to eliminate cervical cancer as a public health problem, the management of cervical cancer continues to evolve with major advances in imaging modalities, surgical approaches, identification of histopathological risk factors, radiotherapy techniques, and biomarker-driven personalized therapies. In particular, the introduction of immune checkpoint inhibitors has dramatically altered the treatment of cervical cancer, leading to significant survival benefits in both locally advanced and metastatic/recurrent settings. As the landscape of cervical cancer therapies continues to evolve, the aim of the present review is to provide a comprehensive discussion of the current state and the latest practice-changing updates in cervical cancer.
宫颈癌是一个重大的全球健康问题，在全球女性中是第四大常见癌症。根据分期、组织学和患者因素，宫颈癌的标准治疗是多种治疗方法的联合，包括（保留或不保留生育功能的）手术、放疗、铂类化疗以及贝伐单抗、免疫检查点抑制剂和抗体药物偶联物等新型全身治疗。尽管雄心勃勃的全球倡议试图消除宫颈癌这一公共卫生问题，但随着成像模式、手术方法、组织病理学危险因素的识别、放疗技术和生物标志物驱动的个性化治疗等方面的重大进展，宫颈癌的治疗仍在不断发展。特别是免疫检查点抑制剂的引入极大地改变了宫颈癌的治疗方式，在局部晚期和转移性/复发性患者中均带来了显著的生存获益。随着宫颈癌治疗格局的不断演变，本综述的目的是全面讨论宫颈癌的现状以及最新的改变实践的进展。
